Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amber Johnson

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
NPJ Precision Oncology|July 15, 2023
Actionability classification of variants of unknown significance correlates with functional effectAmber Johnson, Patrick Kwok-Shing Ng, Michael Kahle, et al.
Oncotarget|May 28, 2015
Clinical next generation sequencing to identify actionable aberrations in a phase I programGenevieve M Boland, Sarina A Piha-Paul, Vivek Subbiah, et al.
Oncotarget|September 10, 2019
Correction: A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratoryNatalia Paez Arango, Lauren Brusco, Kenna R Mills Shaw, et al.
Oncotarget|April 19, 2017
A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratoryNatalia Paez Arango, Lauren Brusco, Kenna R Mills Shaw, et al.
NPJ Precision Oncology|March 20, 2021
Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) studyApostolia Maria Tsimberidou, David S Hong, Siqing Fu, et al.
Nature Reviews. Clinical Oncology|January 6, 2026
The actionable transcriptome: a framework for incorporating RNA sequencing into precision oncologyAmber Johnson, Yifei Shen, Xiaofeng Zheng, et al.
Journal of the National Cancer Institute|April 12, 2015
A decision support framework for genomically informed investigational cancer therapyFunda Meric-Bernstam, Amber Johnson, Vijaykumar Holla, et al.
NPJ Precision Oncology|October 27, 2022
Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncologyHenry Hiep Vo, Siqing Fu, David S Hong, et al.
International Journal of Cancer|August 19, 2024
Representation of women in clinical trials supporting FDA-approval of contemporary cancer therapiesSujay Kalathoor, Sanam Ghazi, Beryl Otieno, et al.
Clinical Chemistry|January 29, 2015
Clinical actionability enhanced through deep targeted sequencing of solid tumorsKen Chen, Funda Meric-Bernstam, Hao Zhao, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
NPJ Precision Oncology|July 15, 2023
Actionability classification of variants of unknown significance correlates with functional effectAmber Johnson, Patrick Kwok-Shing Ng, Michael Kahle, et al.
Oncotarget|May 28, 2015
Clinical next generation sequencing to identify actionable aberrations in a phase I programGenevieve M Boland, Sarina A Piha-Paul, Vivek Subbiah, et al.
Oncotarget|September 10, 2019
Correction: A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratoryNatalia Paez Arango, Lauren Brusco, Kenna R Mills Shaw, et al.
Oncotarget|April 19, 2017
A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratoryNatalia Paez Arango, Lauren Brusco, Kenna R Mills Shaw, et al.
NPJ Precision Oncology|March 20, 2021
Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) studyApostolia Maria Tsimberidou, David S Hong, Siqing Fu, et al.
Nature Reviews. Clinical Oncology|January 6, 2026
The actionable transcriptome: a framework for incorporating RNA sequencing into precision oncologyAmber Johnson, Yifei Shen, Xiaofeng Zheng, et al.
Journal of the National Cancer Institute|April 12, 2015
A decision support framework for genomically informed investigational cancer therapyFunda Meric-Bernstam, Amber Johnson, Vijaykumar Holla, et al.
NPJ Precision Oncology|October 27, 2022
Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncologyHenry Hiep Vo, Siqing Fu, David S Hong, et al.
International Journal of Cancer|August 19, 2024
Representation of women in clinical trials supporting FDA-approval of contemporary cancer therapiesSujay Kalathoor, Sanam Ghazi, Beryl Otieno, et al.
Clinical Chemistry|January 29, 2015
Clinical actionability enhanced through deep targeted sequencing of solid tumorsKen Chen, Funda Meric-Bernstam, Hao Zhao, et al.
Pageof 8